Table 1. Patient Clinical Characteristics According to Treatment.
| Variable | LEV (n = 312) |
LTG (n = 231) |
P value | IPTW-adjusted, P value |
|---|---|---|---|---|
| Age at ASM prescription, median (IQR), y | 17 (14-20) | 17 (15-22) | .10 | .96 |
| History of febrile seizures, No. (%) | 30 (9.6) | 17 (7.4) | .40 | .97 |
| Family history of epilepsy in a 1st- or 2nd-degree relative, No. (%) | 99 (31.7) | 80 (35.1) | .40 | .99 |
| Psychiatric comorbidities, No. (%) | 37 (11.9) | 39 (16.9) | .10 | .99 |
| Mild intellectual disability, No. (%) | 10 (3.2) | 10 (4.3) | .50 | .95 |
| Epilepsy syndrome | ||||
| Absence epilepsy, No. (%) | 48 (15.4) | 61 (26.4) | <.001 | .99 |
| Juvenile myoclonic epilepsy, No. (%) | 162 (51.9) | 97 (42) | ||
| Epilepsy with GTCS alone, No. (%) | 102 (32.7) | 73 (31.6) | ||
| Previous status epilepticus, No. (%) | 15 (5.1) | 4 (1.8) | .06 | .96 |
| Catamenial worsening of seizures, No. (%) | 49 (15.9) | 36 (15.8) | >.99 | .99 |
| History of photosensitivity, No. (%) | 99 (32.1) | 63 (27.8) | .30 | .99 |
Abbreviations: ASM, antiseizure medication; GTCS, generalized tonic-clonic seizures; IPTW, inverse probability of treatment weighting; LEV, levetiracetam; LTG, lamotrigine.